High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease
- PMID: 12913407
- DOI: 10.1023/a:1025013213192
High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease
Abstract
Menorrhagia is one of the most important and frequent complications in women with congenital von Willebrand disease (vWD). Three cases of menorrhagia with vWD (type 1; 1 case, type 2A; 2 cases) were successfully treated with tranexamic acid at dose of 3 grams daily in four divided doses for the first 5 days of the menstrual cycle. All patients had severe menorrhagia lasted for more than 10 days with iron deficiency anemia of hemoglobin levels of 6.5-8.4 g/dl. Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1-5 of their menstrual cycles did not correct their menorrhagia. The treatment was then changed to the daily dose of 3 grams in 4 divided doses on days 1-5 of their menstrual cycles. Thereafter, their menorrhagia became well-controlled with improvement of their anemia up to hemoglobin of 11.5-12.4 g/dl. High dose of tranexamic acid has been administered safely in all patients for 3-5 years without significant complications. Oral high-dose administration of tranexamic acid is very convenient and useful for treatment of menorrhagia in the patients with vWD.
Similar articles
-
Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid.Haemophilia. 1998 Jan;4(1):63-5. doi: 10.1046/j.1365-2516.1998.00147.x. Haemophilia. 1998. PMID: 9873869
-
Von Willebrand factor for menorrhagia: a survey and literature review.Haemophilia. 2016 May;22(3):397-402. doi: 10.1111/hae.12898. Epub 2016 Feb 4. Haemophilia. 2016. PMID: 26843404 Free PMC article. Review.
-
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.Lancet Haematol. 2023 Aug;10(8):e612-e623. doi: 10.1016/S2352-3026(23)00119-9. Epub 2023 Jun 26. Lancet Haematol. 2023. PMID: 37385272 Free PMC article. Clinical Trial.
-
Tranexamic acid: a review of its use in the management of menorrhagia.Drugs. 2003;63(13):1417-33. doi: 10.2165/00003495-200363130-00008. Drugs. 2003. PMID: 12825966 Review.
-
Treatment of menorrhagia in von Willebrand's disease.Haemophilia. 1999 Jan;5(1):76. doi: 10.1046/j.1365-2516.1999.00286.x. Haemophilia. 1999. PMID: 10215952 No abstract available.
Cited by
-
A benefit-risk review of systemic haemostatic agents: part 2: in excessive or heavy menstrual bleeding.Drug Saf. 2008;31(4):275-82. doi: 10.2165/00002018-200831040-00001. Drug Saf. 2008. PMID: 18366238 Review.
-
Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis.Wien Klin Wochenschr. 2017 May;129(9-10):303-316. doi: 10.1007/s00508-017-1194-y. Epub 2017 Apr 21. Wien Klin Wochenschr. 2017. PMID: 28432428 Free PMC article. Review.
-
Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.ACS Med Chem Lett. 2014 Feb 18;5(5):538-43. doi: 10.1021/ml400526d. eCollection 2014 May 8. ACS Med Chem Lett. 2014. PMID: 24900876 Free PMC article.
-
Tranexamic acid has no effect on postoperative pain control after arthroscopic rotator cuff repair: A prospective, double-blind, randomized controlled trial.Asia Pac J Sports Med Arthrosc Rehabil Technol. 2023 Aug 31;33:32-35. doi: 10.1016/j.asmart.2023.08.003. eCollection 2023 Jul. Asia Pac J Sports Med Arthrosc Rehabil Technol. 2023. PMID: 37693817 Free PMC article.
-
Expert consensus on the diagnosis and treatment of thrombocytopenia in adult critical care patients in China.Mil Med Res. 2020 Apr 3;7(1):15. doi: 10.1186/s40779-020-00244-w. Mil Med Res. 2020. PMID: 32241296 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources